Invent announces NMPA acceptance of a new indication application for sintilimab for the treatment of advanced melanoma. Company announcement - FT.com.
Invent announces NMPA acceptance of a new indication application for sintilimab for the treatment of advanced melanoma. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in